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ARTICLE
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Autism spectrum disorders (ASDs) are a heterogeneous group of disorders with unknown aetiology. Even
though ASDs are suggested to be among the most heritable complex disorders, only a few reproducible
mutations leading to susceptibility for ASD have been identified. In an attempt to identify ASD
susceptibility genes through chromosome rearrangements, we investigated a female patient with
childhood autism and high-grade myopia, and an apparently balanced de novo translocation,
t(5;18)(q34;q12.2). Further analyses revealed a 3.2 Mb deletion encompassing 17 genes at the 18q break
point and an additional deletion of 1.27 Mb containing two genes on chromosome 4q35. Q-PCR analysis of
14 of the 17 genes deleted on chromosome 18 showed that 11 of these genes were expressed in the brain,
suggesting that haploinsufficiency of one or more genes may have contributed to the childhood autism
phenotype of the patient. Identification of multiple genetic changes in this patient with childhood autism
agrees with the most frequently suggested genetic model of ASDs as complex, polygenic disorders.
European Journal of Human Genetics (2008) 16, 312–319; doi:10.1038/sj.ejhg.5201985; published online 9 January 2008
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Introduction
Childhood autism is a neurodevelopmental disorder with
onset in early childhood. It is characterized by impairment
of social interaction and communication accompanied by
stereotypic behaviour or interests with onset of symptoms
before the age of 3. The prevalence of childhood autism is
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estimated to be between 10 and 60 in 10 0001 – 3 with a
male to female ratio of four to one.4 Cumulative evidence
from family and twin studies suggests that childhood
autism is among the most heritable complex disorders with
a concordance rate of 60–90% in monozygotic twins and a
recurrence rate of 2–3% in siblings of affected probands.4,5
The mode of inheritance is unknown, but the broad
phenotypic variation together with the limited overlap in
the numerous genome scans performed in autistic cohorts
suggests genetic heterogeneity.6
Characterizing chromosomal rearrangements at the
molecular level is an approach to identify disease or
susceptibility genes for complex disorders. This approach
makes no assumptions on the mode of inheritance or
aetiological overlap with other patients and has success-
fully revealed disease genes for monogenic disorders as well
as susceptibility genes for multifactorial disorders.7 – 9 By
combining this method with whole-genome screening
methods, like array-based comparative genome hybridiza-
tion (array CGH), it is possible to identify combinations of
gene alterations that may confer susceptibility to complex
disorders. We used this combined approach to identify
potential susceptibility genes for childhood autism in a
patient with a de novo translocation, t(5;18)(q34;q12).
Methods
Participants
The translocation patient The patient is a 38-year-old
Danish woman with a de novo translocation
t(5;18)(q34;q12). She is the first of two children of
unrelated and healthy parents. Her younger sister is
phenotypically normal. At birth, her mother was 21 and
her father was 24 years old. She was born at term after a
pregnancy with reduced intrauterine movement as de-
scribed by the mother. Delivery was prolonged and
asphyxia was noted at birth. Birth weight was 2500 g and
birth length was 50 cm. Later in life, mild cerebral palsy,
hyper flexible joints, excessive myopia (12 dioptres, right
eye; 11 dioptres, left eye), and hypersensitivity to sounds
were observed. She did not have any dysmorphic features.
She sat at 9 months of age, walked alone when 17 months
old, and said her first words and sentences at 42 months of
age. At 3 years of age, she was diagnosed with childhood
autism. She attended a school for autistic children until the
age of 18 years and afterwards she moved to an institution
for autistic adults. At the age of 34 years, she was tested
with Autism Diagnostic Observation Schedule (ADOS)10
module 4 for adults with fluent speech, and her mother
was interviewed with Autism Diagnostic Interview-Revised
(ADI-R).11 Both tests clearly showed that the patient
fulfilled the criteria for a childhood autism diagnosis as
defined in the International Classification of Diseases,
tenth revision (ICD-10). In the ADOS test, the patient
scored 7 points in both the ‘communication’ area (autism
cut-off 3) and ‘qualitative impairment in reciprocal social
interaction’ area (autism cut-off 6), and thus, the total
score was 14 points (autism cut-off 10). The results from
the ADI-R gave equivalently a score of 27 in the ‘qualitative
impairment in reciprocal social interaction’ area (autism
cut-off 10); a score of 18 in the ‘communication’ area
(autism cut-off 8); and a score of 9 in the ‘restricted,
repetitive behaviour’ area (autism cut-off 3). At the same
time, the Wechsler Adult Intelligence Scale-Revised (WAIS-R)
showed a verbal IQ of 78, a performance IQ of 105, and a
full IQ of 88. Today, she lives in a small sheltered house for
adult autistic patients.
The National Ethics Committees and the Danish Data
Protection Agency approved the study, and informed
consent was obtained.
Patients used for sequencing analysis For mutation
screening, DNA from a total of 32 high-grade myopia
patients and 157 autistic patients was collected. The
high-grade myopia patients were collected at The Kennedy
Institute – National Eye Clinic (Glostrup, Denmark).
One hundred autistic patients were recruited at the
Hospital Pedia´trico de Coimbra, originating from mainland
Portugal and the Azorean islands. The male–female ratio
was 4.8:1, and the ages ranged between 2 and 18 years
(mean age 6.8 years). Idiopathic subjects were included
after clinical assessment and screening for known medical
and genetic conditions associated with autism, including
testing for Fragile X mutations (FRAXA and FRAXE),
chromosomal abnormalities, neurocutaneous syndromes,
endocrine (thyroid function screening), and metabolic
disorders. Another 35 children diagnosed with childhood
autism were recruited at child psychiatric hospitals in the
western part of Denmark (Jutland) (age range 3–30 years,
with mean age of 10 years and male–female ratio of 3:1).
Part of the sample has been described elsewhere.12 Thirteen
autistic patients were ascertained at Kennedy Institute –
National Eye Clinic (Glostrup, Denmark). These patients
were all unrelated and were part of the IMGSAC group.
Assessment methods and inclusion criteria have previously
been described.13 Eleven of the thirteen patients had
siblings and some even additional relatives with a perva-
sive developmental disorder diagnosis. Four patients
diagnosed within the autism spectrum were collected at
Psychiatric Hospital (Frederiksborg Amt, Denmark). In all
of these 152 patients, childhood autism was diagnosed
in accordance with DSM-IV14 or ICD-1015 criteria using
ADI-R in addition to ADOS or the Childhood Autism
Rating Scale.10,16 In addition, five DNA samples from
autism spectrum disorder (ASD) patients with chromoso-
mal rearrangements were included. Two of these DNA
samples were collected at the Wilhelm Johannsen Centre
for Functional Genome Research, University of Copenha-
gen (Denmark) and were from Danish men diagnosed with
childhood autism in accordance with ICD-10. Two DNA
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samples from a Swedish, male twin couple were collected at
the Department of Clinical Genetics, University Hospital
Lund (Sweden) and one male DNA sample was collected by
James Lespinasse at Laboratoire de Genetique Chromoso-
mique, Centre hospitalier Chambery (Chambery, France).
These three patients have an ASD diagnosis but have not
been diagnosed according to ICD-10 or DSM-IV.
Whole-genome DNA amplification
When necessary DNA samples were genome amplified
using GenomiPhit DNA Amplification Kit (GE Healthcare,
Buckinghamshire, UK).
The Phi29 WGA kit (Amplicon, Brighton, UK) was used
to amplify DNA from blood spots.
Fluorescence in situ hybridization
Metaphase chromosomes were prepared from peripheral
blood lymphocytes, and the karyotype of the translocation
patient was determined by G-banding. Fluorescence in situ
hybridisation (FISH) was performed using 250 ng biotin-14-
dATP-labelled bacterial artificial chromosome (BAC) clones
from the RPCI-11 library according to standard protocols.
Array CGH
Array CGH with a whole-genome 32K BAC array was
performed for the translocation patient as described
previously.17
Real-time quantitative PCR analysis (RT Q-PCR)
cDNA synthesis of mRNA or total RNA (tissues used listed
in Supplementary Table S1A and S1B) (Clontech, CA, USA)
was performed using SuperScript II reverse transcriptase
(Invitrogen) according to manufacturer. cDNA was inves-
tigated for DNA contamination by PCR using three primer
pairs located in a region with no known genes (Supple-
mentary Table S2). Real-time quantitative PCR (RT Q-PCR)
analysis was carried out on a DNA Engine Opticon 2
(Bio-Rad, Go¨teborg, Sweden) using LightCycler FastStart
DNA MasterPLUS SYBR GreenI (Roche, Hvidovre, Denmark).
From 12 analysed housekeeping genes, 6 were selected for
normalization by using the BestKeeper software.18 Primers
used are listed in Supplementary Table S3.
In situ hybridization
Coronal cryostat sections (12 mm thick) of the mouse brain
were prepared and mounted on Superfrost Pluss slides. The
sections were hybridized as previously described19 with
three 38-mer 35S-labelled oligonucleotide probes comple-
mentary to Brunol4 mRNA. An oligonucleotide probe was
used as sense control (Supplementary Table S4).
Images of the sections on X-ray film were transferred to a
computer using a light box, a COHU 4912 high-perfor-
mance CCD camera, and Image 1.42 software (Wayne
Rasband, NIH, Bethesda, MD, USA). The pictures were
visualized with Adobe Photoshop 7.0.
Sequencing
Mutation analysis of the BRUNOL4 gene (NM_020180) was
carried out by direct sequencing of all the 12 coding exons
and exon–intron boundaries in 157 ASD patients and 32
high-grade myopia patients. The sequencing reactions
were carried out by Macrogen Inc. in Korea (http://
www.macrogen.com/), and ChromasPro version 1.33
(Technelysium Pty Ltd, Australia) was used to analyse the
data. Primers and conditions are listed in Supplementary
Table S5.
Results
The chromosome break points of the translocation patient
were characterized by FISH. On chromosome 5, the BAC
clone RP11-541P9 was spanning the break point, while
RP11-256N5 was proximal and RP11-2A20 was distal. No
known genes were located within this break point region.
On chromosome 18, an approximately 3.2 Mb microdele-
tion containing 17 annotated RefSeq genes and two
ultraconserved sequences (UCSs)20 was identified (Supple-
mentary Table S6; Figure 1). At the proximal deletion break
point, BAC clone RP11-812d8 (chr18:30 184–30 378 Mb;
NCBI35; HG17) was present and RP11-108g18 (chr18:
30 197–30 378 Mb; NCBI35; HG17) was deleted. At the
distal break point, the fosmid clone G248P85590D6
(chr18:33 355–33 392 Mb; NCBI35; HG17) was deleted
and the BAC clone RP11-1147p1 (chr18:33 276–
33 467 Mb; NCBI35; HG17) was present. FISH analyses of
the parents showed that the deletion occurred de novo.
Presence of microdeletions/duplications elsewhere in
the genome was investigated by array CGH. Apart from the
deletion at the 18q break point, a deletion of approxi-
mately 1.2 Mb was identified at 4q35 (RP11-215A19 to
RP11-746B09; chr4:187 648–188 915 Mb; NCBI35; HG17).
This deletion comprised two RefSeq genes: MTNR1A
(Melatonin receptor 1A) and FAT (Human homologue of
the Drosophila fat tumour suppressor gene). Presence of
the deletion was confirmed by FISH analyses, which
showed that the deletion was inherited from the father.
As the published information on most of the genes
deleted at 18q12 was sparse, we determined the tissue
expression profile of 14 of the 17 deleted genes by
RT Q-PCR. Dystrobrevin alpha (DTNA) and polypeptide
N-acetylgalactosaminyltransferase (GALNT1) were already
well described and were therefore not included in this
study, and KIAA1328 was not annotated at the time of
investigations. Eleven of the fourteen genes were expressed
in fetal and/or adult brain (normalized expression pattern
of the 14 genes in human brain tissue is shown in Figure 2).
BRUNOL4 expression was much higher in both fetal and
adult brain than any of the other genes (Supplementary
Table S1A), and we therefore investigated the tissue
expression pattern of this gene further with mRNA in situ
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hybridization on mouse brain sections. A strong hybridiza-
tion signal for Brunol4 was detected in the mouse
neocortex, striatum, cerebellum, amygdala, hippocampus,
piriform cortex, and hypothalamus (Figure 3). We further
investigated involvement of BRUNOL4 in ASD and myopia,
by sequencing 157 ASD patients and 32 high-grade myopia
patients.21,22 Three new silent nucleotide changes were
identified within the coding region of BRUNOL4 in three
unrelated ASD patients and submitted to the NCBI SNP
database: ss67005831, ss67005837, and ss67005840.
Furthermore, two new silent nucleotide changes within
the coding region were identified in two unrelated high-
grade myopia patients and were also submitted to the NCBI
SNP database: ss67005834 and ss67005843.
Discussion
In a female patient diagnosed with childhood autism and
a de novo translocation t(5;18)(q34;q12), we identified a
3.2 Mb deletion encompassing 17 genes (Figure 1) at the
18q12 translocation break point and a 1.27 Mb deletion on
chromosome 4q35. Since chromosomal imbalances are
known causes of mental retardation and other congenital
anomalies,23 and comorbidity of mental retardation with
autism is a frequent finding, it is likely that deletion of one
or more genes in this patient may lead to the observed
childhood autism phenotype due to haploinsufficiency.
On chromosome 4, two known genes, MTNR1A (Mela-
tonin receptor 1A) and FAT (homologue of Drosophila
tumour suppressor fat), and an approximately 900 kb
gene desert located 50 to these genes were deleted
(chr4:187 648–188 915 Mb, NCBI35; HG17). These dele-
tions were inherited from the father, who had ADHD-like
features. Previously, five copy number variations have
been identified in this area (Database of Genomic Variants;
http://projects.tcag.ca/variation/). Three normal control
subjects have duplications of a large area of chromosome
4q35 encompassing MTNR1A and FAT (chr4:188 251–
188 282 Mb, NCBI35; HG17).24 Another normal control
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subject has a duplication of the gene desert 30 to MTNR1A
and FAT (chr4:187 636–187 797 Mb, NCBI35; HG17),25
whereas two different normal controls have duplications
(chr4:188 251–188 282 Mb, NCBI35; HG17)26 and
(chr4:188 353–189 810 Mb, NCBI35; HG17), and one has
a deletion of the gene desert 50 to MTNR1A and FAT
(chr4:188 260–188 262 Mb, NCBI35; HG17).27 Deletion of
the MTNR1A and FAT genes is not reported in normal
control subjects, but in a patient with an unknown
phenotype, a deletion including MTNR1A, FAT, and six
other genes was reported during screening of large-scale
variations in the human genome.28 Moreover, in a patient
with schizoaffective disorder a 4q deletion possibly con-
taining the FAT gene has been published.29 The FAT gene is
expressed in the eye and CNS in addition to other tissues,
and encodes a protein of the cadherin superfamily of cell
Figure 3 In situ hybridization for mRNA transcript of Brunol4 on coronal sections of mouse brain. The montage shows images on X-ray films of
hybridized coronal sections from rostral to caudal levels (a–g). A coronal section of the forebrain, hybridized with a sense probe, is seen in h.
am¼ amygdala; ce¼ cerebellum; de¼dentate gyrus; hy¼hypothalamus; hi¼hippocampus; ma¼mammillary nuclei; mg¼medial geniculate body;
pi¼piriform cortex; sp¼ septum; sr¼ striatum; su¼ superior colliculus; te¼ tegmental area; th¼ thalamus.
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adhesion molecules that is involved in cell migration, cell–
cell contact, and establishment of cell polarity.30 It has
recently been suggested that FAT and its protein partners
might be components of a molecular pathway involved in
susceptibility to bipolar disorder.31 Several lines of evi-
dence suggest that neuropsychiatric disorders such as
ASDs, schizophrenia, and bipolar disorder have common
susceptibility genes32 – 34 and FAT might be one of these.
MTNR1A encodes a melatonin receptor in the brain that is
mainly involved in transmitting the effect of melatonin on
circadian rhythm.35 Since biological rhythm disturbances
are often reported in patients with mood disorders and a
low melatonin level has been reported in individuals with
ASDs, it is possible that haploinsufficiency of MTNR1A
confer susceptibility to ASD.35,36
The deletion on chromosome 18 is at chromosome
position chr18:30 197–33 392 Mb (NCBI35; HG17). A large
number of deletions of varying sizes and locations on the
long arm of chromosome 18 have already been pub-
lished.37 – 41 However, most of the deletions that apparently
overlap with the present deletion have not been fine
mapped, which complicates genotype/phenotype correla-
tions. The most common features of the 18q12 deletion
patients described in the literature are very mild dys-
morphic features hardly disclosed at birth, psychomotor
delay, hypotonia, ataxia, some degree of mental retarda-
tion, and behavioural abnormalities.39 These features
indicate that one or more genes within this region are
crucial for development and normal function of the brain.
McEntagart et al42 have recently reported a patient with
del(18)(q11.2q12.2). Even though the precise break points
of this deletion are unknown, it apparently includes the
same 17 known genes identified in the present case
(Figure 4). In this region, there is a 4.4 Mb large evolu-
tionary stable gene desert43 and 5 UCSs. UCSs are defined
as sequences Z200 bp with 100% identity in the human,
mouse, and rat genome,20,44 and some UCSs have been
shown to posses enhancer activity,45 suggesting that they
are involved in gene regulation and development.20,44 The
presence of a stable gene desert as well as five UCSs in this
region suggests that one or more of the deleted genes are
developmentally important.
The phenotypic similarities of the present case and the
patient reported by McEntagart and colleagues (Table 1),
suggest that haploinsufficiency of one or more of the 17
deleted genes may lead to the common features. Tissue
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Figure 4 Deletion in the present case is depicted together with the minimal and maximal deleted region in the subject described by McEntagart.
RefSeq genes are positioned in accordance with the UCSC genome browser, March 2006 assembly.
Table 1 Phenotype comparison of the present case to the
patient reported by McEntagart et al42
Phenotypes Present case McEntagart
Hypotonia No Yes
Febrile convulsions No Yes
Cerebral paresis Yes No
Delayed psychomotor development Yes Yes
Delayed language development Yes Yes
Behavioural difficulties Yes Yes
IQ 85 61
Autism Yes NR
Myopia Yes NR
NR, not reported.
Identical traits are written in bold.
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expression profiles of 14 of these genes showed that 11 of
them were expressed in the brain (Figure 2). Furthermore,
these genes code for proteins, which may be involved in
the normal functioning of the central nervous system; a
zinc transporter (SLC39A6) that assures cofactors for
hundreds of cellular enzymes;46 four zinc finger transcrip-
tion factors (ZNF397, ZNF396, ZNF271, ZNF24); a scaffold-
ing protein (STATIP1) of the JAK-STAT signalling pathway
suggested to be involved in neuronal and glial cell
proliferation, survival, and differentiation;47 – 49 an O-
glycosylating enzyme (GALNT1) that might enable cells
to adhere, differentiate, and migrate;50 a microtubule
associated protein (MAPRE2) that is possibly involved in
the development of neuronal processes,51 and an RNA-
binding protein (BRUNOL4) that is most likely involved in
mRNA splicing, regulation of translation, and rate of
mRNA turnover.21,52 The properties of these genes there-
fore suggest that each of them may have contributed to the
ASD phenotype of the patient. Further studies should
therefore be carried out to assess the involvement of
these genes in ASDs using large patient and control
cohorts.
We investigated one of the genes, BRUNOL4, further as
this gene might be of interest with regards to the combined
myopia and childhood autism phenotype observed in the
present case, since it is expressed in the developing eye21,22
as well as in the brain areas most consistently found to be
affected in neuropathological investigations of autism (the
limbic system, cerebellum, and cerebral cortex53) (Supple-
mentary Table S1A and S1B; Figure 3). Moreover, BRUNOL4
expression was significantly higher in both fetal and adult
brain than any other gene residing in the deleted region. In
addition, this gene belongs to the bruno-like elav (em-
bryonic lethal abnormal visual system) family of
genes,21,52 which result in abnormal eye and brain
development in Drosophila when mutated.54 – 56 We
therefore sequenced the coding region of BRUNOL4 in
157 ASD patients and 32 high-grade myopia patients,
and identified 5 silent nucleotide substitutions that are
most likely not involved in the development of myopia
and/or ASDs. However, further studies including larger
patient and control cohorts are necessary to investigate
involvement of BRUNOL4 in the aetiology of autism and/or
myopia.
In conclusion, we have identified deletion of 19
genes in a patient with myopia and childhood autism,
and one or more of these genes might have contributed
to the development of these features. In addition,
positional effects of the deletions and the translocation
break points, and the asphyxia at birth may have
contributed to the phenotype observed in this patient.
Identification of multiple genetic changes in a patient with
childhood autism is in line with the most frequently
suggested genetic model of ASDs as complex, polygenic
disorders.
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